| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, January 9, 2018 GlaxoSmithKline CEO Emma Walmsley has grabbed headlines with some of the top management changes she’s made since taking the helm in March, namely poaching Luke Miels from rival AstraZeneca to head up pharmaceuticals, and appointing Roche and Calico veteran Hal Barron as CSO. But behind the scenes, her scalpel has actually cut much deeper. |
|
|
| This week's sponsor is Biotech Primer. | | | |
Top Stories Of The Week Sunday, January 7, 2018 A new journal paper published late last week revealed that a “cutting” element of the CRISPR-Cas9 gene-editing technique could be under threat from the body’s own immune system. Monday, January 8, 2018 The 2018 J.P. Morgan Healthcare Conference is starting to recede in biopharma's rearview mirror, but industry watchers are still digesting the comments from top executives and analysts—and the news announcements, sparse as they were. Monday, January 8, 2018 On the first day of the big biotech conference that is J.P. Morgan, Celgene has come right out on day one with M&A news. Wednesday, January 10, 2018 Teva has worked out agreements with workers to close another plant in Israel. That is two down and about 40 to go. Monday, January 8, 2018 After running four months without a proper new name following the completion of the $7.4 billion merger, INC Research and inVentiv Health were finally reborn as Syneos Health. Thursday, January 4, 2018 Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader. Yet Manon Cox says the departure wasn't on her terms, according to the Meriden Record-Journal. Thursday, January 4, 2018 While oncolytic viruses have seen limited success in humans as a monotherapy, two studies show that they could be more effective as part of combination treatments for breast and brain cancers. Wednesday, January 10, 2018 People often ask Bristol-Myers Squibb CEO Giovanni Caforio how much growth is still ahead for Eliquis, the next-gen anticoagulant the company shares with Pfizer. His answer? Plenty. Wednesday, January 10, 2018 Illumina, the maker of DNA sequencers, unveiled its latest device. With a price tag of just under $20,000, the company hopes it will open the doors for more researchers to study viruses, bacteria and other microbes. | This week's sponsor is Veeva. | | | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? From study delays to quality issues, sponsors can find their studies at risk with no clear solution. Sponsored by: Veeva Systems Expanding into new markets places a spotlight on inefficient processes. Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Presented By: Patheon When a biologics company prepares to launch a new product, it must forecast the capacity it will need. Download Patheon's whitepaper to learn how to mitigate risks by developing a manufacturing strategy that will accommodate a forecast range and allow you to adapt as better data becomes available. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. |
